Initiatives aim to spur development of drugs for rare diseases

04/25/2011 | Google

Several initiatives are encouraging pharmaceutical companies to bolster development of drugs for rare and neglected medical conditions. The NIH is set to launch in the fall a scientific center to transform genetic discoveries into therapies, while the International Rare Diseases Research Consortium is aiming for at least 200 more orphan drugs by 2020. Furthermore, senators introduced a bipartisan bill that would give drugmakers an incentive to developing treatments for children with rare diseases.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC